Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03303547

Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Imperial College London · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration. This trial aims to determine if image mapping techniques can improve the concordance between imaging and pathology detection of tumour deposits. Lymph nodes and tumour deposits will be identified on pre-operative scans and mapped by radiologists then shared with pathologists prior to processing the resected specimen. Patients will be managed at their local hospital with standard follow-up. Patients will be followed up for 5 years.

Detailed description

A prospective interventional multi-centre study, COMET aims to prove the accuracy of imaging diagnosis of extranodal tumour deposits (TD) and their adverse effect on prognosis of colorectal cancers. The proposed intervention will be additional radiological and pathological assessment and the reporting of supplementary diagnostic information which would not otherwise have been available. This may affect treatment according to local MDT protocols and also affect the provision of prognostic information to patients in subsequent discussions.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTMRI mapping to guide pathological sampling of extranodal tumour depositsRadiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.

Timeline

Start date
2017-10-16
Primary completion
2026-12-01
Completion
2031-12-01
First posted
2017-10-06
Last updated
2024-10-17

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03303547. Inclusion in this directory is not an endorsement.